An Upcoming Catalyst At Impax Laboratories
Michael Hagan - at Seeking Alpha - Thu Dec 18, 10:57AM CST
IPXL: 31.32 (+0.26)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 31.32 (+0.26), CHTP: 6.52 (-0.03), SUPN: 8.52 (+0.15), ITCI: 17.99 (+0.16), LLY: 70.16 (+0.42), DRRX: 0.81 (-0.01)
Actavis to Appeal Ruling Regarding Namenda IR Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 16, 5:20PM CST
Actavis plc (ACT) announced its decision to file an emergency appeal for an immediate overturn of the lower court ruling that will require the company to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Actavis Likely to Continue Selling Namenda IR Tablets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Dec 12, 2:20PM CST
Actavis plc (ACT) may face an injunction under which the company will have to continue selling Namenda IR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
First patient enrolled in Acorda Phase 3 PD trial
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 7:06AM CST
IPXL: 31.32 (+0.26), ADMS: 16.10 (+1.45), TEVA: 57.09 (+0.33), ACOR: 39.14 (+0.74), PRTA: 20.14 (+1.41), NDRM: 5.90 (-0.19)
Impax Laboratories Has Returned 21.1% Since SmarTrend Recommendation (IPXL)
Comtex SmarTrend(R) - Fri Dec 05, 5:03PM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 2 months, Impax Laboratories has returned 21.14% as of today's recent price of $32.40.
IPXL: 31.32 (+0.26)
Migraine - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/xq8n9b/migraine) has announced the addition of the "Migraine - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Migraine - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ache Laboratorios Farmaceuticos - Alder Biopharmaceuticals - Allergan - Amgen - Astellas Pharma - Avanir Pharmaceuticals - BioDelivery Sciences - Biofrontera - Bristol-Myers Squibb - D-Pharm - Eli Lilly and Company - Heptares Therapeutics - Impax Laboratories - IntelGenx - Istituto Italiano di Tecnologia - Medestea Research & Production - Merck & Co - Nektar Therapeutics - Northern Light Pharmaceuticals - Paladin Labs - Pfizer - Pozen - Proreo Pharma - Questcor Pharmaceuticals - Revance Therapeutics - TheraJect - Transcept Pharmaceuticals - Trigemina - Vertex Pharmaceuticals Incorporated - iCeutica For more information visit http://www.researchandmarkets.com/research/xq8n9b/migraine
VRTX: 115.15 (+1.40), AMGN: 160.67 (+3.15), LLY: 70.16 (+0.42), BMY: 59.15 (-0.01), NKTR: 15.02 (+0.23), AGN: 210.12 (+0.95), IPXL: 31.32 (+0.26), ALDR: 25.67 (+0.43), QCOR: 93.60 (+1.52), MRK: 57.46 (+0.25), TSPT: 1.70 (-0.04), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07)
Valeant's Onexton Gel Gets FDA Approval for Acne - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 5:30PM CST
Valeant Pharmaceuticals International, Inc.'s (VRX) Onexton Gel received FDA approval for acne vulgaris (including non-inflammatory comedonal and inflammatory acne).
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44), ALXN: 181.96 (+3.09), GSK: 42.85 (+0.11)
UCB-Daiichi Sankyo Ink Deal to Sell Vimpat in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 01, 2:20PM CST
UCB SA (UCBJF) and Daiichi Sankyo have signed a deal to jointly commercialize Vimpat for the treatment of epilepsy in Japan.
IPXL: 31.32 (+0.26), VRX: 140.33 (-0.22), SCMP: 13.75 (+0.44)
Shares of IPXL Up 22.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Nov 28, 11:04AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 2 months, Impax Laboratories has returned 22.23% as of today's recent price of $32.69.
IPXL: 31.32 (+0.26)
Is Impax Laboratories (IPXL) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 28, 7:57AM CST
Impax Laboratories is one stock that might be an intriguing choice for investors as it is seeing solid earnings estimate revision and has a Zacks Industry Rank of 29
IPXL: 31.32 (+0.26)
Johnson & Johnson's Rezolsta Approved in the EU for HIV-1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 27, 12:20PM CST
Johnson & Johnson (JNJ) gained EU approval for its HIV-1 drug, Rezolsta.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), JNJ: 104.59 (+0.31), GILD: 91.29 (+1.84)
Insys' Cannabidiol Gets another Orphan Drug Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 9:40AM CST
Insys Therapeutics, Inc.'s (INSY) pharmaceutical cannabidiol (CBD) candidate received orphan drug designation from the FDA for the treatment of pediatric schizophrenia.
IPXL: 31.32 (+0.26), AGN: 210.12 (+0.95), LCI: 42.29 (+1.79), INSY: 41.52 (+0.51)
Supernus Files Trokendi XR Patent Infringement Lawsuit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 24, 5:00PM CST
Supernus Pharmaceuticals, Inc. (SUPN) filed a patent infringement lawsuit against Zydus accusing the latter of infringement of three patents covering Trokendi XR.
IPXL: 31.32 (+0.26), ACT: 254.20 (-1.68), SUPN: 8.52 (+0.15), MYL: 56.97 (+0.39)
Agios (AGIO) Shares Up on Positive AG-120 Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 20, 3:33PM CST
Shares of Agios Pharmaceuticals (AGIO) soared 14.51% after the company reported positive safety and clinical data on pipeline candidate, AG-120, from an ongoing phase I dose escalation study.
IPXL: 31.32 (+0.26), BIIB: 340.89 (+5.13), AGIO: 109.67 (+2.45), CELG: 109.60 (+3.48)
Uptrend Call Working As Impax Laboratories Stock Rises 12.8% (IPXL)
Comtex SmarTrend(R) - Thu Nov 20, 9:27AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on October 9th, 2014 at $26.75. In approximately 1 month, Impax Laboratories has returned 12.84% as of today's recent price of $30.18.
IPXL: 31.32 (+0.26)
Mallinckrodt Q4 Earnings Boosted by Acquisitions, Sales Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 9:07AM CST
Mallinckrodt (MNK) reported adjusted earnings of $1.68 per share in the fourth quarter of fiscal 2014, beating the Zacks Consensus Estimate of $1.34. Earnings were above the year-ago figure of 98 cents per share.
IPXL: 31.32 (+0.26), MNK: 97.84 (-0.29), BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39)
Corium International (CORI) Jumps: Stock Moves 14.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:25AM CST
Corium International (CORI) was a big mover last session, with shares rising over 14% on the day.
IPXL: 31.32 (+0.26), CORI: 6.00 (-0.44), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)
Is Mallinckrodt (MNK) Poised to Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 4:30PM CST
Mallinckrodt plc (MNK) is set to report fourth-quarter fiscal 2014 results on Nov 19.
IPXL: 31.32 (+0.26), MNK: 97.84 (-0.29), BIIB: 340.89 (+5.13), MYL: 56.97 (+0.39)
AxoGen (AXGN) Looks Good: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:46AM CST
AxoGen (AXGN) was a big mover last session, with shares rising nearly 6% on the day.
IPXL: 31.32 (+0.26), AXGN: 3.85 (+0.17), AKRX: 36.47 (+0.43), MYL: 56.97 (+0.39)